{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: Randomised Controlled Trial of Ticagrelor vs. Clopidogrel in Post-CABG Patients"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "receiving either aspirin plus clopidogrel (A+C) or aspirin plus ticagrelor (A+T)"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcomes were all-cause mortality and cardiovascular mortality, assessed over a follow-up period."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation methods and allocation concealment varied across studies"
      },
      "Blinding": {
        "score": 0,
        "evidence": "blinding details were inconsistently reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "A+T was associated with a decreased risk of all-cause mortality (OR=0.47, 95% CI 0.31\u20130.70, p<0.001) and cardiovascular mortality (OR=0.50, 95% CI 0.31\u20130.82, p=0.006) compared to A+C."
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not consistently reported across studies."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: PROSPERO CRD42022330721."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 9,
    "max_score": 25
  },
  "model": "gpt-4o"
}